Literature DB >> 11482987

Production and neurotropism of lentivirus vectors pseudotyped with lyssavirus envelope glycoproteins.

N Desmaris1, A Bosch, C Salaün, C Petit, M C Prévost, N Tordo, P Perrin, O Schwartz, H de Rocquigny, J M Heard.   

Abstract

We investigated the production efficiency and the gene transfer capacity in the central nervous system of HIV-1-based vectors pseudotyped with either the G protein of the Mokola lyssaviruses (MK-G), a neurotropic virus causing rabies disease, or the vesiculo-stomatitis G protein (VSV-G). Both envelopes induced syncitia in cell cultures. They were incorporated into vector particles and mature virions were observed by electron microscopy. Vector production was two- to sixfold more efficient with VSV-G than with MK-G. For equivalent amounts of physical particles, vector titration was 5- to 25-fold higher with VSV-G than with MK-G pseudotypes on cultured cells, and in vivo gene expression in mouse brain was more intense. Thus, VSV-G pseudotypes were produced more efficiently and were more infectious than MK-G pseudotypes. Tropism for brain cells was analyzed by intrastriatal injections in rats. Both pseudotypes preferentially transduced neurons (70-90% of transduced cells). Retrograde axonal transport was investigated by instilling vector suspensions in the rat nasal cavity. Both pseudotypes were efficiently transported to olfactive neuron bodies. Thus, although coating HIV-1 particles with rabdhovirus envelope glycoproteins enables them to enter neuronal cells efficiently, pseudotyping is not sufficient to confer the powerful neurotropism of lyssaviruses to lentivirus vectors. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11482987     DOI: 10.1006/mthe.2001.0431

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  28 in total

Review 1.  Viral vectors for gene delivery to the central nervous system.

Authors:  Thomas B Lentz; Steven J Gray; R Jude Samulski
Journal:  Neurobiol Dis       Date:  2011-10-07       Impact factor: 5.996

Review 2.  Altering the tropism of lentiviral vectors through pseudotyping.

Authors:  James Cronin; Xian-Yang Zhang; Jakob Reiser
Journal:  Curr Gene Ther       Date:  2005-08       Impact factor: 4.391

3.  Retrovirus glycoprotein functionality requires proper alignment of the ectodomain and the membrane-proximal cytoplasmic tail.

Authors:  Sanath Kumar Janaka; Devon A Gregory; Marc C Johnson
Journal:  J Virol       Date:  2013-09-18       Impact factor: 5.103

Review 4.  Viral vectors: from virology to transgene expression.

Authors:  D Bouard; D Alazard-Dany; F-L Cosset
Journal:  Br J Pharmacol       Date:  2009-05       Impact factor: 8.739

5.  Visualization of targeted transduction by engineered lentiviral vectors.

Authors:  K-I Joo; P Wang
Journal:  Gene Ther       Date:  2008-05-15       Impact factor: 5.250

Review 6.  Methods for gene transfer to the central nervous system.

Authors:  Boris Kantor; Rachel M Bailey; Keon Wimberly; Sahana N Kalburgi; Steven J Gray
Journal:  Adv Genet       Date:  2014       Impact factor: 1.944

7.  Chimeric rabies SADB19-VSVg-pseudotyped lentiviral vectors mediate long-range retrograde transduction from the mouse spinal cord.

Authors:  L Schoderboeck; S Riad; A M Bokor; H E Wicky; M Strauss; M Bostina; M J Oswald; R M Empson; S M Hughes
Journal:  Gene Ther       Date:  2015-01-29       Impact factor: 5.250

Review 8.  Virus infections in the nervous system.

Authors:  Orkide O Koyuncu; Ian B Hogue; Lynn W Enquist
Journal:  Cell Host Microbe       Date:  2013-04-17       Impact factor: 21.023

Review 9.  Recent gene therapy advancements for neurological diseases.

Authors:  Sahana Nagabhushan Kalburgi; Nadia N Khan; Steven J Gray
Journal:  Discov Med       Date:  2013-02       Impact factor: 2.970

10.  Vpu-dependent block to incorporation of GaLV Env into lentiviral vectors.

Authors:  Ilias Christodoulopoulos; Magali E Droniou-Bonzom; Jill E Oldenburg; Paula M Cannon
Journal:  Retrovirology       Date:  2010-01-26       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.